These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30409757)

  • 1. Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism.
    Kang KS; Hong JM; Horan DJ; Lim KE; Bullock WA; Bruzzaniti A; Hann S; Warman ML; Robling AG
    Bone; 2019 Mar; 120():166-175. PubMed ID: 30409757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.
    Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG
    J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The high-bone-mass phenotype of novel transgenic mice with LRP5 A241T mutation.
    Wang X; Zhang H; Hu L; He J; Jiang Q; Ren L; Yu K; Fu M; Li Z; He Z; Zhu J; Wang Y; Jiang Z; Yang G
    Bone; 2024 Oct; 187():117172. PubMed ID: 38909879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
    Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
    Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
    Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T
    J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanotransduction in bone tissue: The A214V and G171V mutations in Lrp5 enhance load-induced osteogenesis in a surface-selective manner.
    Niziolek PJ; Warman ML; Robling AG
    Bone; 2012 Sep; 51(3):459-65. PubMed ID: 22750014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Missense Mutations in LRP5 Associated with High Bone Mass Protect the Mouse Skeleton from Disuse- and Ovariectomy-Induced Osteopenia.
    Niziolek PJ; Bullock W; Warman ML; Robling AG
    PLoS One; 2015; 10(11):e0140775. PubMed ID: 26554834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of multiple bone responses to graded strains above functional levels, and to disuse, in mice in vivo show that the human Lrp5 G171V High Bone Mass mutation increases the osteogenic response to loading but that lack of Lrp5 activity reduces it.
    Saxon LK; Jackson BF; Sugiyama T; Lanyon LE; Price JS
    Bone; 2011 Aug; 49(2):184-93. PubMed ID: 21419885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The LRP5 high-bone-mass mutation causes alveolar bone accrual with minor craniofacial alteration.
    Turkkahraman H; Flanagan S; Zhu T; Bellido TM; Yuan X
    J Periodontal Res; 2023 Aug; 58(4):723-732. PubMed ID: 37128744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes.
    Niziolek PJ; Farmer TL; Cui Y; Turner CH; Warman ML; Robling AG
    Bone; 2011 Nov; 49(5):1010-9. PubMed ID: 21855668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling.
    Rhee Y; Allen MR; Condon K; Lezcano V; Ronda AC; Galli C; Olivos N; Passeri G; O'Brien CA; Bivi N; Plotkin LI; Bellido T
    J Bone Miner Res; 2011 May; 26(5):1035-46. PubMed ID: 21140374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRP1 Suppresses Bone Resorption in Mice by Inhibiting the RANKL-Stimulated NF-κB and p38 Pathways During Osteoclastogenesis.
    Lu D; Li J; Liu H; Foxa GE; Weaver K; Li J; Williams BO; Yang T
    J Bone Miner Res; 2018 Oct; 33(10):1773-1784. PubMed ID: 29750835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High bone mass in mice expressing a mutant LRP5 gene.
    Babij P; Zhao W; Small C; Kharode Y; Yaworsky PJ; Bouxsein ML; Reddy PS; Bodine PV; Robinson JA; Bhat B; Marzolf J; Moran RA; Bex F
    J Bone Miner Res; 2003 Jun; 18(6):960-74. PubMed ID: 12817748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
    Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
    J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of miR-29 Activity in the Myeloid Lineage Increases Response to Calcitonin and Trabecular Bone Volume in Mice.
    Shin B; Hrdlicka HC; Delany AM; Lee SK
    Endocrinology; 2021 Oct; 162(10):. PubMed ID: 34192317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5.
    Frost M; Andersen T; Gossiel F; Hansen S; Bollerslev J; van Hul W; Eastell R; Kassem M; Brixen K
    J Bone Miner Res; 2011 Aug; 26(8):1721-8. PubMed ID: 21351148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An RNA-seq protocol to identify mRNA expression changes in mouse diaphyseal bone: applications in mice with bone property altering Lrp5 mutations.
    Ayturk UM; Jacobsen CM; Christodoulou DC; Gorham J; Seidman JG; Seidman CE; Robling AG; Warman ML
    J Bone Miner Res; 2013 Oct; 28(10):2081-93. PubMed ID: 23553928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D receptor expression in mature osteoclasts reduces bone loss due to low dietary calcium intake in male mice.
    Starczak Y; Reinke DC; Barratt KR; Russell PK; Clarke MV; Davey RA; Atkins GJ; Anderson PH
    J Steroid Biochem Mol Biol; 2021 Jun; 210():105857. PubMed ID: 33647520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
    Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
    Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of overexpression of Lrp5 on orthodontic tooth movement.
    Holland R; Bain C; Alrasheed RS; Robling AG; Utreja A
    Orthod Craniofac Res; 2021 Aug; 24(3):430-437. PubMed ID: 33326696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.